Anti-Human MET Recombinant Antibody (ABT-700) (CAT#: TAB-521CL)

Figure 1 Survival curves of mice with metastatic EBC1 tumors treated with ABT-700.

Primary tumors established after subcutaneous inoculation of EBC1 cells were surgically removed and ABT-700 at 10 mg/kg, Q21D, was administered with several schedules (start and end day) as shown. Growth of metastases in the lung caused death of animals and mortality was monitored over 530 days.

Wang, J., Goetsch, L., Tucker, L., Zhang, Q., Gonzalez, A., Vaidya, K. S., ... & Pestova, E. (2016). Anti-c-Met monoclonal antibody ABT-700 breaks oncogene addiction in tumors with MET amplification. BMC cancer, 16(1), 105.

Figure 2 Immune-blots of signaling and apoptosis pathway molecules in SNU5 cells treated with 10 μg/mL ABT-700 for 24h.

Wang, J., Goetsch, L., Tucker, L., Zhang, Q., Gonzalez, A., Vaidya, K. S., ... & Pestova, E. (2016). Anti-c-Met monoclonal antibody ABT-700 breaks oncogene addiction in tumors with MET amplification. BMC cancer, 16(1), 105.

Figure 1 Anti-Human MET Therapeutic Antibody (ABT-700) (TAB-521CL) in ELISA

ELISA analysis of TAB-521CL was performed by coating with Recombinant Human MET Protein.

Figure 2 Anti-Human MET Therapeutic Antibody (ABT-700) (TAB-521CL) in WB

Western blot analysis of TAB-521CL was performed with Recombinant Human MET Protein
Lane 1: Non-Reducing Antigen (0.5μg)
Lane 2: Reducing Antigen (0.5μg)